Estados Unidos · Plataformas y datos · MarketBeat

Krystal Biotech (NASDAQ:KRYS) Given New $412.00 Price Target at Citigroup

Publicado por MarketBeat · Estados Unidos hace 1 h

Citigroup decreased their price objective on shares of Krystal Biotech from $416.00 to $412.00 and set a "buy" rating on the stock in a report on Tuesday.

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Krystal Biotech (NASDAQ:KRYS) Given New $412.00 Price Target at Citigroup

También te puede interesar

AIRO Group offers upside as military drone demand accelerates: Roth Capital

ServiceNow Stock: Buy the Dip?

My wife and I have no kids and a 99% chance of outliving our life savings. Why not spend it all?

Stock market after midterm elections: What S&P 500 history shows

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

3 Vanguard Bond ETFs That Mail Retirees a Check Every Month. Here’s What They Paid

Krystal Biotech (NASDAQ:KRYS) Given New $412.00 Price Target at Citigroup

Compartir

También te puede interesar

AIRO Group offers upside as military drone demand accelerates: Roth Capital

ServiceNow Stock: Buy the Dip?

My wife and I have no kids and a 99% chance of outliving our life savings. Why not spend it all?

Stock market after midterm elections: What S&P 500 history shows

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

3 Vanguard Bond ETFs That Mail Retirees a Check Every Month. Here’s What They Paid